-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $1030

Benzinga·08/03/2026 14:22:14
Listen to the news
Guggenheim analyst Brad Canino maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Buy and raises the price target from $1000 to $1030.